Favorable outcome of COVID-19 in a young woman with severe Crohn's disease on regular use of adalimumab and prednisone: a case report.
Rev Inst Med Trop Sao Paulo
; 62: e102, 2020.
Article
in English
| MEDLINE | ID: covidwho-983846
ABSTRACT
COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn's disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn's disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Prednisone
/
Crohn Disease
/
Adalimumab
/
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Rev Inst Med Trop Sao Paulo
Year:
2020
Document Type:
Article
Affiliation country:
S1678-9946202062102
Similar
MEDLINE
...
LILACS
LIS